APX-115 free base NEW
| Price | $51 | $122 | $198 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: APX-115 free base | CAS No.: 1270084-92-8 |
| Purity: 99.03% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | APX-115 free base |
| Description | APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with inhibition constants (Kis) of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4, respectively, and it effectively prevents kidney injury. |
| In vitro | In the mouse podocyte cell line, APX-115 free base (5?μM; 60?min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression. In the kidney, APX-115 free base attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes [2]. |
| In vivo | APX-115 free base treatment decreases the urinary excretion of albumin and plasma creatinine levels. APX-115 (oral gavage; 60?mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 245 mg/mL (877.07 mM), Sonication is recommended. |
| Keywords | plasma | APX 115 free base | NOX | Inhibitor | injury | Nox1 | kidney | Ewha18278 | albumin | Ewha 18278 | APX115 free base | Ewha-18278 | insulin | APX115 | Nox3 | resistance | APX-115 | NADPH Oxidase | inhibit | APX-115 free base | APX 115 | creatinine | Nox2 |
| Inhibitors Related | Metronidazole | Ketoconazole | Resveratrol | Pasiniazid | ML-090 | APX-115 | Dicoumarol | NAD+ | Apocynin | Triclosan | AKR1C1-IN-1 | Setanaxib |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-11 | |
| $0.00/1kg |
VIP5Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 | |
| $51.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY